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Prioritization of COVID-19 vaccination
Evidence-based recommendations
Immunizationa b s t r a c t
National Immunization Technical Advisory Groups are groups of multi-disciplinary experts that provide
scientific advice to policy makers to enable them to make informed immunization policy and programme
decisions. NITAGs faced challenges using their routine approach to develop recommendations for COVID-
19 vaccines during the pandemic. In response, the WHO Regional Office for Europe (Regional Office), with
the support of the Robert Koch Institute, developed an innovative approach of a series of webinars, pro-
vision of materials, and remote technical assistance to address these challenges. Polls conducted during
webinars were used to tailor future webinars and evaluate the effectiveness of these interventions.
According to poll results, 76% of participants found the webinars and resources shared very useful in their
work on COVID-19 vaccination. The Regional Office plans to build further upon the scope of online com-
munication and establish a regional online platform for NITAGs to further support NITAGs and build
capacity.
 2021 World Health Organization. Published by Elsevier Ltd.1. Introduction
The COVID-19 pandemic is unprecedented and has exacted an
enormous toll on individuals, families, communities and societies
around the world. In April 2021, the WHO European Region (the
Region) surpassed 1 million confirmed COVID-19 deaths; 1.6 mil-
lion new cases were reported every week [1]. Vaccines against
COVID-19 offer hope in containing the pandemic, protecting healthcare systems, saving lives and restoring global economies. Vaccine
availability is limited as manufacturing of first vaccines reach full
capacity and additional vaccines come to market. As part of defin-
ing an appropriate national strategy for COVID-19 vaccination,
governments were therefore required to make decisions on the
most efficient use of the limited vaccine supply to reduce infec-
tions, prevent severe and fatal disease and protect essential
services.
National Immunization Technical Advisory Groups (NITAGs)
play an important role in enabling ministries of health (MoH)
and governments to make evidence-informed decisions by provid-
ing scientific advice [2,3]. NITAG’s evidence-based recommenda-
tions increase the credibility of MoH or government decisions,
and thereby acceptance by health care professionals and the public
[4,5].
In late 2020, NITAGs faced challenges using their routine
approach to develop recommendations for COVID-19 vaccines
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including data on safety and efficacy, as well as insufficient data
on disease epidemiology. In addition, NITAGs struggled to stay
up-to-date on rapidly evolving information about COVID-19 dis-
ease, risk factors for developing severe disease and death and the
development of multiple vaccines with different profiles and new
technologies. This struggle of NITAGs was compounded by a lack
of professional networking, usually done through in-person meet-
ings, which could not be held due to the pandemic. In addition,
some Member States had an extremely short timeframe between
vaccine licensure and rollout, which forced NITAGs to assess avail-
able evidence in parallel to national or regional regulators based on
partially published or evolving data.
The WHO Regional Office for Europe (Regional Office) has been
providing constant support to newly established NITAGs to
improve their functioning and ability to make evidence-based rec-
ommendations. The Regional Office conducted regional trainings,
provided support to NITAGs in adopting a systematic approach
for recommendation-making, and facilitated peer-to peer learning
and collaboration between NITAGs and the European Technical
Advisory Group of Experts on Immunization (ETAGE) and the
Strategic Advisory Technical Group of Experts on Immunization
(SAGE) [6].
The Regional Office developed an innovative approach to
address challenges posed by the COVID-19 pandemic and to sup-
port NITAGs in making recommendations on COVID-19 vaccination
and continue building the capacity of NITAGs in the Region within
the limitations of the COVID-19 pandemic environment.1 www.covid19infovaccines.com2. Description of the NITAG support
Considering the scope of the use of the available technology, the
Regional Office started new online communication channels (webi-
nars) and regular e-mail correspondence to establish an effective
two-way communication with NITAGs. The Regional Office con-
ducted a series of webinars to provide updated information and
guidance on COVID-19 vaccines and vaccination, share Member
States’ experiences and challenges in developing recommenda-
tions, and identify NITAG needs with regards to developing
national COVID-19 vaccination recommendations to allow WHO
and partners to provide appropriate support. Beginning in October
2020, the Regional Office, supported by the Robert Koch Institute
within the domain of the ongoing joint project to strengthen the
capacity of NITAGs of middle-income countries in the Region, con-
ducted webinars every 3–4 weeks for NITAGs, National Immuniza-
tion Programme (NIP) Managers and other national stakeholders
from the 53 Members States of the Region, representatives of
WHO country offices andWHO national and international partners.
The webinars topics are outlined in Table 1. The focus of the webi-
nars was to facilitate dissemination and enhance the understand-
ing of recommendations made by WHO SAGE and ETAGE on
COVID-19 vaccination and raise awareness on evolving data on
COVID-19 vaccines in pipeline.
Furthermore, resources for NITAGs to use when developing rec-
ommendations were presented and specific guidance on how to
adopt regional and global recommendations and how to develop
recommendations using a systematic approach were given. Mem-
ber States had the opportunity to share their experiences on devel-
oping national recommendations by their NITAG and rolling out
vaccination campaigns and to pose questions to leading national
and international experts.
The Regional Office undertook efforts to ensure that all parties
interested and involved in the development of national recommen-
dations on COVID-19 vaccination had an opportunity to participate
in these webinars. A comprehensive list of national stakeholders6596and WHO and partner organizations’ staff was developed and used
to send out invitations to participate in the webinars. To reduce
any bottlenecks for interested parties to participate, the webinars
did not require pre-registration and country participants were
encouraged to forward webinar invitations to relevant colleagues
and counterparts involved in the development of recommenda-
tions on COVID-19 vaccination in their country. The list was
updated after each webinar to add new participants. In countries
with slow internet connection, national counterparts were invited
to attend the webinars from WHO country offices. The number of
people and Member States participating during each webinar are
provided in Table 1. National stakeholders from 50 out of 53
(94%) Member States participated in at least one webinar and 24
out of 53 (45%) Member States participated in all five webinars
conducted for all Member States. Most participants (approximately
32%) were NITAG chairs, members, and their secretariats and
approximately 15% of participants were MoH officials, members
of COVID-19 task forces and working groups and NIP Managers.
The remaining participants were representatives of national public
health agencies and institutes, as well as WHO staff and represen-
tatives of national and international partners.
The webinars were conducted in English and Russian languages
with simultaneous interpretation and presentation slides in both
languages were shared with all people invited to the webinars.
The slides were disseminated in editable format to facilitate trans-
lation into local languages.
Webinar participants were encouraged to submit questions
during and after the webinars. The Regional Office, together with
experts who presented during the webinars and the WHO Collab-
orating Center for Vaccine Safety, provided detailed responses to
questions and distributed them in writing to all participants as
follow-up to the meetings. The answers to the most common ques-
tions were made available in different formats (video, text, pod-
cast) and languages (English, Russian, Spanish) at a WHO
Collaborating Center for Vaccine Safety website on COVID-19 vac-
cines and vaccination1.
In addition to the webinars, the Regional Office provided regular
updates on available information and resources on COVID-19 vac-
cines to all participants invited to the webinars through e-mail cor-
respondence. These updates included webinar materials and new
and updated WHO guidelines and documents in both English and
Russian languages.
The Regional Office provided direct technical support (re-
motely) to ten NITAGs who requested assistance including discus-
sion on WHO recommendations on prioritization of target groups,
providing additional data and information, and providing feedback
on recommendations drafted for NITAG deliberation.2.1. Webinar follow-up and impact
The Regional Office conducted polls during the November,
December 2020 and March 2021 webinars to monitor Member
States’ progress in developing NITAG recommendations on
COVID-19 vaccination strategies and learn about NITAGs’ chal-
lenges and needs. The polls allowed participants to provide feed-
back on how the Regional Office could further support NITAGs in
developing COVID-19 vaccination recommendations, on topics to
be discussed at future webinars, how the webinar format could
be improved, and the usefulness of the webinar topics and materi-
als. Selected results from these polls can be seen in Figs. 1-3.
During the November 2020 meeting, participants were asked
about the main challenges experienced when developing recom-
mendations (Fig. 1). Most participating Member States reported
Table 1
Topics, number of participants, and number of Member States by income level participating in webinars on COVID-19 vaccination for National Immunization Technical Advisory
Groups, organized by the WHO Regional Office for Europe.
Date Topics Number of participating Member




HI UMI LMI LI
8 & 9 Oct 2020(for UMI and
LMI Members States)
・SAGE Roadmap for prioritizing uses of COVID-19 vaccines in the context
of limited supply
15 (108) 0 10 3 0
・Recommendations developed by NITAGs on target groups for COVID-19
vaccination (United Kingdom, United States)
29 Oct 2020(for HI Member
States)
・SAGE Roadmap for prioritizing uses of COVID-19 vaccines in the context
of limited supply
21 (77) 21 0 0 0
・Recommendations developed by NITAGs on prioritization of target
groups for COVID-19 vaccination (Germany, Belgium, France)
・Market authorization of COVID-19 vaccines in the EU region:
methodology and process of the European Medicines Agency
・SYSVAC2: Global registry of systematic reviews on vaccination and
online course
19 Nov 20204 (for all
Members States)
・ETAGE recommendation on regional adaptation of SAGE Roadmap for
prioritizing uses of COVID-19 vaccines
43 (226) 25 13 4 1
・COVID-19 vaccines in pipeline
10 Dec 20204 (for all
Members States)
・COVID-19 vaccines in pipeline 46 (166) 27 14 4 1
・SAGE guidance for the development of evidence-based vaccination
related recommendations
・Results from umbrella review on risk factors for severe/fatal COVID-19
19 Jan 2021 (for all
Members States)
・SAGE recommendation on Pfizer-BioNTech COVID-19 vaccine 48 (220) 28 14 5 1
・Preliminary data from post-marketing surveillance on adverse events
following immunization from the European Medicines Agency
・Country experiences launching COVID-19 vaccines (Croatia, Israel,
United Kingdom)
18 Feb 2021 (for all
Members States)
・COVID-19 vaccine in phase 3 trials 43 (1805) 26 12 4 1
・SAGE recommendation on Moderna and AstraZeneca COVID-19 vaccine
・Country experiences launching COVID-19 vaccines (Germany, Denmark,
Romania)
・Developing (interim) recommendation for COVID-19 vaccines – process
and resources from WHO Europe
25 Mar 20214 (for all
Members States)
・SAGE recommendation on Janssen COVID-19 vaccine 45 (150) 26 14 4 1
・Statement of the WHO GACVS on safety signals related to Astra Zeneca
COVID-19 vaccine
・SYSVAC2: Global registry of systematic reviews on vaccination and
online course
1 According to information provided by participants in their Zoom Participant Name or in Zoom meeting report. The actual number of participating countries may be higher
because not all participants indicated their country (approximately 10% of participants of each webinar did not indicate their country).
2 According to unique connections captured by Zoom. The actual number of participants was higher because in some countries, experts gathered in meeting rooms and used
one Zoom connection to participate in webinars.
3 Based on the World Bank country classification by income level: 2020–2021 (https://datahelpdesk.worldbank.org/knowledgebase/articles/378834-how-does-the-world-
bank-classify-countries) (Accessed 23 August 2021)
4 Poll was conducted during this webinar
5 The representatives of WHO Country Office, South Africa from the WHO African Region participated in this webinar
Abbreviations: SAGE, Strategic Advisory Group of Experts on Immunization; NITAG, National Immunization Technical Advisory Group; SYSVAC, global registry of systematic
review on vaccination; ETAGE, European Technical Advisory Group of Experts; WHO, World Health Organization; GACVS, Global Advisory Committee on Vaccine Safety; HI,
High Income; UMI, Upper Middle Income; LMI, Lower Middle Income; LI, Low Income.
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ing Member States experienced lack of time to work on the devel-
opment of COVID-19 vaccination recommendations.
To evaluate the usefulness of the webinars and their impact on
Member States, the Regional Office asked participants during the
25 March 2021 webinar to indicate the topics of past webinars
which were most useful to them and to evaluate the webinars
and the materials shared. Most participants found the presentation
of SAGE recommendations on BioNTech-Pfizer and AstraZeneca
COVID-19 vaccines, the European Medicines Agency preliminary
data from post-marketed surveillance on adverse events following
immunization and country experiences on recommendations on
the prioritization of target groups for COVID-19 vaccination and
implementation of COVID-19 vaccination useful (Fig. 2).
The results of polls conducted during the November and
December 2020 meetings showed Member States’ progress in
developing national recommendations on COVID-19 vaccination
strategy, to which regional webinars may have contributed. During
the November meeting 8 of 32 (25%) participating Member States6597reported developing national strategies; during the December
meeting 16 of 32 (50%) participating Member States reported that
they had national recommendations in place, including 17 out of
the 29 Member States that had participated in the previous poll.
76% of participants found the webinars and resources shared
very useful in their work on COVID-19 vaccination (Fig. 3). Further-
more, 25/29 (86%) of participants reported they would be inter-
ested in future Regional webinars on different topics, even when
the COVID-19 pandemic is under control and 3/29 (10%) reported
they would be interested in future webinars if they were in addi-
tion to in-person meetings.
2.2. Products and tools developed
Addressing the expressed challenges, the Regional Office devel-
oped an Operational guidance on evidence-based decision-making
process for developing national COVID-19 vaccination strategies
[7] to provide guidance to NITAGs in developing recommendations







0% 20% 40% 60% 80% 100%
Difficules in adopng global and regional guidance tools
Lack of available informaon in local language
Lack of robust in-country data
Difficules in applying systemac approach to the
development of recommendaon
Lack of me of NITAG members and other experts to work
on the recommendaons
Lack of available evidence on COVID-19 vaccines
Fig. 1. Outline of challenges indicated by 39 Member States participating in poll conducted during WHO European Regional webinar on Preparedness for COVID-19














0% 20% 40% 60% 80%
Registry on systemac reviews (SYSVAC)
Review on risk factors for severe/fatal COVID-19
Country experiences: implementaon of COVID-19…
Country experiences: recommendaon on priorizaon…
EMA preliminary data from post-markeng surveillance…
EMA methodology/process for COVID-19 vaccines…
Update on COVID-19 vaccines in pipeline
SAGE recommendaon on AstraZeneca COVID-19 vaccine
SAGE recommendaon on Moderna COVID-19 vaccine
SAGE recommendaon on BioNTech-Pfizer COVID-19…
ETAGE recommendaon on priorizaon of target groups
SAGE guidance for developing of evidence-based…
SAGE values framework and roadmap
Fig. 2. Webinar topics indicated as useful for developing recommendations on COVID-19 vaccination by 38 participants who took part in poll conducted during WHO
European Regional webinar on COVID-19 Vaccination held on 25 March 2021 (% of participants). Abbreviations: AEFI, adverse events following immunization; EMA, European
Medicines Agency; ETAGE, European Technical Advisory Group of Experts on Immunization; SAGE, Strategic Advisory Group of Experts on Immunization; SYSVAC, global
registry of systematic reviews on vaccination.














How useful were the Regional Webinars for your work on COVID-19 vaccinaon?
How useful were the resources shared aer the webinar?
Fig. 3. Participant rating of usefulness of Regional webinars on COVID-19 vaccination and resources shared after the webinar based on responses from 41 participants during
WHO European Regional webinar on COVID-19 Vaccination held on 25 March 2021 (% of participants).
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adapting SAGE and ETAGE advice. Furthermore, the Regional Office
is developing a guidance tool to support recently established
NITAGs in introducing a systematic evidence-to-recommendation
approach, adapted to their level of maturity, in their process of
developing recommendations on vaccines.
2.3. NITAG participation in other meetings
These regular contacts between the Regional Office and NITAGs
in the Region helped to quickly disseminate information and facil-
itate participation of NITAGs in global online meetings, including
SAGE and Global NITAG Network (GNN) webinars [8,9] and WHO
regional webinars on monitoring COVID-19 vaccine uptake, effec-
tiveness, impact and vaccine safety. NITAGs from 33 Member
States participated in SAGE meetings, which were held from 5 to
7 October 2020, on 5 January 2021 and on 8 February 2021. In
the past, NITAG representatives from two Member States attended
each SAGE in-person meeting.
3. Discussion and future plans
This new approach of regular and timely two-way communica-
tion helped NITAGs to increase their knowledge and access neces-
sary information, and ultimately develop national
recommendations on COVID-19 vaccination. This approach helped
the Regional Office tailor support to NITAGs in the challenging
COVID-19 environment by using questions, feedback, and requests
for direct technical support received during and between webinars,
and though poll results. This led to a tailored selection of webinar
topics, improvement of webinars’ format and development of a
guidance tool on using a systematic process to develop recommen-
dations on vaccines.
The experience of using webinars to convey important informa-
tion will change the future work of the Regional Office. Although
virtual meetings will not completely replace in-person meetings
and trainings, they do provide new opportunities. Virtual meetings6599will allow for more frequent communication, timely distribution of
information and guidelines, and easier participation of highly qual-
ified international experts who are not always available for in-
person meetings. Furthermore, this format allows online trainings
which can include all members of NITAGs and their secretariats as
well as varied interested colleagues from MoH, public health insti-
tutes and others and ultimately may demonstrate more value for
money than organizing in-person meetings. This approach may
also facilitate participation of NITAG members in other country’s
NITAG meetings as observers (i.e., peer-to-peer learning).
Based on lessons learned and demonstrated impact, the Regio-
nal Office plans to build further upon the scope of online commu-
nication and establish a regional online platform for NITAGs in the
Region, which will foster opportunities for enhanced collaboration.
Such a platform could also allow NITAGs to share documents and
information, arrange virtual meetings, and provide a platform for
peer-to-peer technical support.
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